Thursday October 1, 2020

Biotech firm Malin’s stake in US drug company plummets by almost €35m

The share price of Poseida Therapeutics has collapsed following the aborting of a safety trial for a prostate cancer drug

Ian Guider

Markets Editor

@ianguider
6th September, 2020
Ian Curley and Darragh Lyons, chief business and financial officer at Malin, the Dublin-based biotech investment fund. Picture: Fergal Phillips.

The value of a stake held by Malin, the Dublin-based biotech investment fund, in a US drug company has fallen by almost €35 million, amid the halting of a safety trial for a prostrate cancer drug due to a patient death.

Malin last week said the value of its 19 per cent stake in Poseida Therapeutics had been marked down to €76.2 million at the end of August, from €110 million at the end of...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Related Stories

Framework for managing nursing homes under new levelled restrictions plan is set to be published this week

Daniel Murray | 4 days ago

As we grapple with the question of post-infection immunity, experts point out that even if a vaccine were found tomorrow, it could not totally eradicate the scourge of coronavirus

Danielle Barron | 4 days ago

Elective care could be paused nationwide as part of contingency plans

Daniel Murray | 4 days ago